(Endometrial Cancer) Is Lenvatinib + Keytruda Effective?
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
- February 3, 2022
- Reading time: 1 minute
On January 19, 2022, Vicky Makker of Memorial Sloan Kettering Cancer Center published results in The New England Journal of Medicine from the Study 309–KEYNOTE-775 Phase III clinical trial evaluating lenvatinib plus the anti-PD-1 antibody Keytruda (pembrolizumab) in advanced endometrial cancer patients with prior platinum-based chemotherapy.
The Study 309–KEYNOTE-775 Phase III trial randomized previously platinum-treated advanced endometrial cancer patients (N=827) in a 1:1 ratio to the lenvatinib arm (lenvatinib 20 mg once daily + Keytruda 200 mg every 3 weeks, N=411) or the chemotherapy arm (N=416). Primary endpoints were progression-free survival (PFS) and overall survival (OS).
Of the 827 patients, 697 were pMMR and 130 were dMMR.
Progression-Free Survival (Primary Endpoint): Median PFS was 7.2 months in the lenvatinib arm versus 3.8 months in the chemotherapy arm, representing a 44% reduction in the risk of progression or death in the lenvatinib arm. Among pMMR patients, median PFS was 6.6 months versus 3.8 months, with a 40% reduction in risk.
Overall Survival (Primary Endpoint): Median OS was 18.3 months in the lenvatinib arm versus 11.4 months in the chemotherapy arm, representing a 38% reduction in the risk of death. Among pMMR patients, median OS was 17.4 months versus 12.0 months, with a 32% reduction in risk.
Safety: Grade ≥3 adverse events occurred in 88.9% of lenvatinib arm patients versus 72.7% in the chemotherapy arm.
Based on the Study 309–KEYNOTE-775 results, Vicky Makker and colleagues concluded that lenvatinib plus Keytruda demonstrated significantly improved PFS and OS compared with chemotherapy in previously platinum-treated advanced endometrial cancer patients.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2108330?query=featured_home
- Immunotherapy
- Clinical trial drugs
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4